Intel stock extends gains after report of possible U.S. government stake
In a recent transaction, Lilly Endowment Inc., a significant shareholder in Eli Lilly & Co. (NYSE:LLY), sold a substantial portion of its holdings. The endowment disposed of 78,025 shares of Eli Lilly’s common stock, generating approximately $87.8 million. The shares were sold on February 21, 2025, at prices ranging from $877.313 to $893.75 per share.
Following this transaction, Lilly Endowment holds 96,544,724 shares of Eli Lilly. The sales were executed in multiple transactions, each with varying prices within the specified range. The endowment remains a major stakeholder in the pharmaceutical giant despite the recent sales. With analysts setting a consensus target price ranging from $620 to $1,190 per share, investors seeking deeper insights can access comprehensive analysis and 17 additional key metrics through InvestingPro’s detailed research report.
In other recent news, Eli Lilly has issued $6 billion in new debt securities across six tranches with maturities ranging from 2028 to 2065, with plans to use the proceeds for general corporate purposes. This debt issuance was managed by a consortium of banks, including Barclays (LON:BARC) Capital Inc. and Goldman Sachs & Co. LLC. Additionally, Moody’s (NYSE:MCO) Ratings upgraded Eli Lilly’s issuer rating to Aa3 from A1, citing expectations of robust earnings growth driven by products like Mounjaro and Zepbound. The upgrade reflects Eli Lilly’s strong competitive position and high profit margins, with the outlook revised to stable. Furthermore, Bernstein analysts maintained an Outperform rating on Eli Lilly, with a price target of $1,100, following the resolution of a semaglutide shortage by the FDA. This is expected to benefit Eli Lilly’s diabetes drugs, Mounjaro and Zepbound, as patients may shift from compounded products to branded drugs. Lastly, Eli Lilly announced that its drug Omvoh has shown sustained efficacy in treating Crohn’s disease, with 92.9% of patients in clinical remission after two years, as presented at the Crohn’s and Colitis Congress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.